Ergomed logo

ERGO - Ergomed News Story

685p -5.0  -0.7%

Last Trade - 9:22am

Sector
Healthcare
Size
Small Cap
Market Cap £334.0m
Enterprise Value £325.2m
Revenue £68.3m
Position in Universe 625th / 1807

Ergomed plc - Ergomed issue of shares

Thu 1st November, 2018 2:44pm
RNS Number : 0825G
Ergomed plc
01 November 2018
 

PRESS RELEASE

FOR IMMEDIATE RELEASE

  

 

 

Ergomed issues 102,491 shares for acquisition and deferred consideration

 

London, UK - 1 November 2018: Ergomed plc, (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, today announces the issue of a total of 102,491 new ordinary shares of 1p each in the Company ("Shares"). Of this amount, 49,390 Shares are being allotted to Dr Michael Forstner as deferred consideration in connection with the acquisition of his epidemiology consulting business announced on 25 May 2018. The remaining 53,101 Shares are being allotted to the seller as part consideration for the acquisition of Pharmacovigilance Services Limited, a small UK-based pharmacovigilance provider with particular expertise in audit and quality management.

 

An application has been made for the admission to trading on AIM of the Shares ("Admission"). Admission is expected to take place at 8.00am on 7 November 2018. The Shares will rank pari passu in all respects with Ergomed's existing shares in issue. Following Admission, the Company's enlarged issued share capital will comprise 44,991,438 Ordinary Shares with one voting right per share. No shares are held in Treasury. The total number of voting rights in the Company is therefore 44,991,438. This figure of 44,991,438 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

 

 Enquiries:

 

Ergomed plc

Tel: +44 (0) 1483 503205

Stephen Stamp (Chief Executive Officer)


Stuart Jackson (Chief Financial Officer)




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)


James Black (Broker)

 


Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

Matthew Neal / Olivia Manser

ergomed@consilium-comms.com



MC-Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke


 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCLLFSSLFLLIIT
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.